Refine by
Respiratory Care Articles & Analysis
28 news found
Marianna University School of Medicine, Department of Respiratory Medicine, Kawasaki, Japan. “Many patients with advanced disease continue to struggle to breathe, making even simple daily tasks difficult. Having a treatment that can help patients breathe easier and live a better quality of life, without surgical intervention, will be a major step forward in COPD ...
(“VIDA”), the leader in lung and respiratory intelligence, announced today that it has received 510(k) clearance from the Food and Drug Administration (FDA) for enhancements to its LungPrint solution, including automated deep learning-based lung and lobe segmentation algorithms. ...
By inhibiting these channels, ENA-001 utilizes the body’s own ventilation control system to stimulate breathing and it does so across multiple causes (etiologies) of respiratory depression. This, and the ability of ENA-001 to address respiratory depression associated with multiple agents (e.g. opioids, benzodiazepines, propofol), differentiates it from ...
Funding from the grant will be used to further the development of ENA001, Enalare's unique agnostic respiratory stimulant for the treatment of respiratory depression due to opioid (prescribed or illicit) overdose/multidrug (polysubstance) overdose in a hospital or community setting. ...
Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening critical care conditions, announced today that it has completed a propofol induced respiratory depression study with its lead compound ENA001, having achieved the targeted primary endpoint. ...
To address the need for better chronic respiratory care, Prof De Backer, emeritus Professor Pulmonology at the University of Antwerp and Chairman of The board of FLUIDDA NV, has opened a private clinic in Belgium near the Fluidda headquarters in Kontich, Belgium. The clinic uses a multidisciplinary approach for chronic respiratory failure. ...
ByFluidda
Outcomes from a previous Lungpacer clinical study published in theFebruary 2022 edition of the American Journal of Respiratory Critical Care Medicine showed Lungpacer therapy strengthened the diaphragm 246% more, and improved lung function 128% more than patients who did not receive the therapy.[1] The growing body of research including more than 44 scientific ...
Enalare is developing multiple agnostic respiratory stimulant products with the potential to improve standard of care for millions of patients. ...
Enalare is planning to develop this unique agnostic respiratory stimulant for a multitude of indications related to acute respiratory depression, including for neonates experiencing Apnea of Prematurity. ...
Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life threatening critical care conditions, announced today that it has filed a Provisional Patent Application with the United States Patent and Trademark Office on its lead product ENA-001 and related compounds for the reversal of respiratory ...
Caroline Baxter, MD, is a Consultant Respiratory Physician at Manchester NHS Foundation Trust in the United Kingdom. ...
Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening critical care conditions, announced today that it has dosed the first subject with its lead product ENA-001 in a propofol-induced respiratory depression study. ...
Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening critical care conditions, announced today that it has been invited to present at the BARDA Industry Day being held virtually Nov. 3-4, 2021. ...
Bothell, Washington - On May 29, 2020, the Centers for Medicare and Medicaid Services (CMS) updated its policy for HCPCS code E0467 (Multi-Function Ventilator) removing “same or similar” restrictions and paving the way for increased access to integrated respiratory care for ventilator users regardless of their device billing history. ...
Patent protected wireless lung function testing technology, Asthma, COPD, and post-COVID syndrome, Spirometry market is predicted to double in 12 months, Globalisation initiative – Europe, SE Asia and the US. Uscom notifies the market of notice to approve CE mark for the Uscom digital ultrasonic SpiroSonic AIR spirometer. The CE mark is recognition of legal compliance with health, safety ...
(“VIDA”), the leader in lung and respiratory intelligence, today announced a new strategic partnership with Peoria, Illinois-OSF HealthCare that will make VIDA Insights available to care teams across the organization. ...
Hogaboam is presently serving on the editorial board of the American Journal of Respiratory and Critical Care Medicine and the Journal of Clinical Investigation Insight. ...
Sam brings over 35 years expertise in many medical fields such as Respiratory Care, Orthopedics and Ophthalmology. Sam held many progressive management roles at Bear Medical, Care Fusion, BD, Alcon, Össur and Salter Labs. ...
These respiratory diseases require a precise determination of gas exchange to detect and treat these illnesses. ...
Northern Ireland headquartered Eakin Healthcare Group has announced it is expanding into a new therapeutic area with the acquisition of Coleraine based Armstrong Medical, which specialises in respiratory care products. The deal represents a diversification for the Group which to date has specialised in ostomy and wound care products. ...